LONDON, April 30 (Reuters) – The head of Europe’s medicines
regulator is digging in for a fight over data transparency after
being stopped from releasing information on drugs from two U.S.
companies by a court ruling.

Defeat for the European Medicines Agency (EMA) at the hands
of AbbVie and Intermune highlights a growing
battle between campaigners for more openness and companies which
fear it will harm their business.

LONDON (Reuters) – Europe’s medicines regulator has been stopped from releasing clinical trial data about drugs made by AbbVie and Intermune, following a court ruling favoring the two U.S. companies.

The European Medicines Agency said on Tuesday it intended to appeal the interim decision by the European Union’s general court.

LONDON (Reuters) – British scientists are stepping up clinical tests of gene therapy in a bid to help people with advanced heart failure pump blood more efficiently.

Researchers said on Tuesday they planned to enroll patients into two new clinical trials using Mydicar, a gene therapy treatment made by privately held U.S. biotech company Celladon.

LONDON, April 25 (Reuters) – AstraZeneca’s sales
fell by a bigger-than-expected 13 percent in the first quarter
as patent expiries took a heavy toll, underscoring the
turnaround challenge facing Britain’s second-largest drugmaker.

Much of the damage was caused by loss of exclusivity on
antipsychotic medicine Seroquel and heart drug Atacand in many
markets.

LONDON (Reuters) – Scientists probing the nature of antimatter have found a bit more evidence to explain why the universe is not an empty husk, although not enough to account for the billions of galaxies strewn across the cosmos.

Physicists believe that equal amounts of matter and antimatter were created in the Big Bang at the birth of the universe 13.8 billion years ago. Within one second, however, the antimatter had all but disappeared.

LONDON (Reuters) – GlaxoSmithKline (GSK.L: Quote, Profile, Research, Stock Buzz) has decided to sell its popular soft drink brands Lucozade and Ribena in a disposal that analysts believe could bring in more than 1 billion pounds ($1.5 billion).

The move was announced on Wednesday alongside weak first-quarter results, which saw sales at Britain’s biggest drugmaker drop 3 percent from a year ago.